Kiora Pharmaceuticals announces 1-for-9 reverse stock split effective June 11, 2024 to meet Nasdaq bid price requirement

KIORA PHARMACEUTICALS INC

1-for-9 reverse stock split filed June 6, 2024; effective at open of market on June 11, 2024.
Outstanding shares will reduce from ~26.7M to ~2.97M; fully diluted from ~100.1M to ~11.1M.
Class D warrants for 3.43M shares expired on June 6, 2024; other warrants adjust proportionally.
No change to authorized shares, par value ($0.01), or ticker (KPRX); fractional shares paid in cash.
Reverse split is intended to maintain compliance with Nasdaq minimum bid price requirement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.